Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study in Mexican adolescents with severe alopecia areata reported that oral tofacitinib treatment resulted in hair growth and reduced alopecia severity without serious adverse effects.

This study observed that hepatotoxicity is a rare but possible event in hyperandrogenic young females treated with low- and ultralow-dose flutamide, regardless of dose or oral contraceptive use.

Medroxyprogesterone acetate improved sleep apnea symptoms in some obese patients.

This review discusses perceptions and side effects of depot medroxyprogesterone acetate and emphasizes the importance of educating teens to enhance compliance; it reports no new clinical findings.

This study found that both tofacitinib and methotrexate effectively reduced hair loss and psychological distress in patients with moderate-to-severe alopecia areata, but tofacitinib showed much greater efficacy. Both treatments had similar safety profiles, with no serious adverse effects reported.

This study found that medroxyprogesterone acetate treatment in women with PCOS reduced hyperandrogenism-related hormonal levels and improved skin conditions without affecting lipid or carbohydrate metabolism.

This study observed that antifungal treatment in fungal asthma patients led to a significant decrease in oral corticosteroid use, though the clinical importance remains unclear due to potential confounders.

This study found that self-reported use of finasteride or oral contraceptives did not reduce the incidence of renal cancer in participants of the PCLO trial.

Oral dutasteride and topical pimecrolimus can safely and effectively treat Frontal Fibrosing Alopecia, leading to significant hair regrowth.

This communication reports previously unreported side effects, severe bullous dermatosis and onycholysis, in three patients undergoing high-dose methotrexate and leucovorin calcium therapy, impacting their chemotherapy schedules.

This abstract discusses the efficacy of spironolactone, cyproterone acetate, and flutamide in treating female pattern hair loss, noting that flutamide use requires caution due to potential liver toxicity, especially at high doses.

This study found that both Diane 35 plus spironolactone and Diane 35 plus finasteride were equally effective and safe for treating hirsutism and acne in Indian women over a 12-month period.

This study reports that hedgehog pathway inhibitors, sonidegib and vismodegib, showed distinct adverse event patterns in real-world data, suggesting the need for further research to confirm these findings.

In this pilot study, both tofacitinib and methotrexate improved alopecia areata outcomes, but tofacitinib showed greater efficacy in achieving significant SALT score improvement after 6 months, although the difference was not statistically significant.

This study found that the compound M50054 inhibits apoptosis by blocking caspase-3 activation and may improve chemotherapy-induced alopecia and hepatitis symptoms.

This study found that mycophenolate mofetil was well tolerated and effective as a second-line treatment for autoimmune hepatitis in patients who were intolerant to azathioprine.

This study reported a 21% partial remission rate in patients with advanced soft tissue sarcomas treated with ifosfamide combination chemotherapy, with no complete remissions observed.

This study found that among adults with severe alopecia areata, alopecia totalis, or alopecia universalis, oral tofacitinib was more effective than methotrexate in reducing hair loss over a 12-week period, though long-term safety and efficacy remain unestablished.

This study found that persistent significant alopecia was a common side effect following FEC-docetaxel chemotherapy, with a 33.4% global incidence, highlighting the need for awareness and potential preventative measures like cooling caps during treatment.

This study found that the oral contraceptive containing drospirenone (EE/DRSP) was as effective as EE/CPA in reducing acne lesions, sebum production, and hair growth in women with acne.

This article reviews pivotal trials and recent findings in chemoprevention for breast, prostate, and colorectal cancers, emphasizing its potential and the importance of further research, public education, and partnerships, but reports no new results.

This study found that flutamide was more effective than spironolactone in reducing symptoms of hirsutism and related conditions in premenopausal women, with fewer discontinuations due to side effects.

This study observed some differences in clinical outcomes when comparing CPA with spironolactone, flutamide, and finasteride, but no differences with other therapies, possibly due to small study size and non-standardized assessments; adverse effects could not be fully compared across treatments.

This study aims to conduct the first double-blind randomized trial comparing spironolactone and doxycycline for female acne treatment, with the goal of establishing spironolactone as a potentially superior alternative, especially given concerns about antibiotic resistance.